Axonopathy in peripheral neuropathies

Mechanisms and therapeutic approaches for regeneration

Lila M. Landowski, P. James B Dyck, Ja Nean Engelstad, Bruce V. Taylor

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Peripheral neuropathies (PNs) are injuries or diseases of the nerves which arise from varied aetiology, including metabolic disease, trauma and drug toxicity. The clinical presentation depends on the type of neuropathy, and may include the loss of motor, sensory and autonomic functions, or development of debilitating neuropathic pain distal to the injury site. It can be challenging to identify the aetiology of PNs, as the clinical syndromes are often indistinct. However, the mechanisms that underlie pathological changes in peripheral neuropathy are fundamentally different, depending on the trigger. This review focuses on the axonopathy observed in two frequently encountered forms of peripheral neuropathy, diabetic neuropathy and chemotherapy-induced neuropathy. A key manifestation of axonopathy in PN is the degeneration of terminal arbors of peripheral nerves, resulting in a loss of epidermal nerve fibres and inappropriate termination of nerve endings. Many symptoms of PN arise from aberrant termination of nerve endings, and the underlying axonopathy may be non-reversible, as nerve regeneration after injury and disease is often poor, absent, or aberrant. Directed guidance of terminal arbors back into the epidermis is therefore a suggested approach to treat peripheral neuropathy. This review will outline potential strategies to enhance and guide axonal regeneration and reinnervation in the skin. Using diabetic neuropathy and chemotherapy-induced neuropathy as specific examples, this review examines the setbacks encountered with the translation of growth factors into therapeutics for human neuropathy, and suggests a number of approaches for topical drug delivery.

Original languageEnglish (US)
Pages (from-to)19-27
Number of pages9
JournalJournal of Chemical Neuroanatomy
Volume76
DOIs
StatePublished - Oct 1 2016

Fingerprint

Peripheral Nervous System Diseases
Regeneration
Nerve Endings
Diabetic Neuropathies
Wounds and Injuries
Therapeutics
Drug Therapy
Nerve Regeneration
Metabolic Diseases
Neuralgia
Drug-Related Side Effects and Adverse Reactions
Peripheral Nerves
Nerve Fibers
Epidermis
Intercellular Signaling Peptides and Proteins
Skin
Pharmaceutical Preparations

Keywords

  • Axonopathy
  • Chemotherapy-induced neuropathy
  • Cisplatin
  • Diabetic neuropathy
  • Paclitaxel
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Axonopathy in peripheral neuropathies : Mechanisms and therapeutic approaches for regeneration. / Landowski, Lila M.; Dyck, P. James B; Engelstad, Ja Nean; Taylor, Bruce V.

In: Journal of Chemical Neuroanatomy, Vol. 76, 01.10.2016, p. 19-27.

Research output: Contribution to journalReview article

@article{5f6b33ad4dd84aff8e1c51cebaed5e28,
title = "Axonopathy in peripheral neuropathies: Mechanisms and therapeutic approaches for regeneration",
abstract = "Peripheral neuropathies (PNs) are injuries or diseases of the nerves which arise from varied aetiology, including metabolic disease, trauma and drug toxicity. The clinical presentation depends on the type of neuropathy, and may include the loss of motor, sensory and autonomic functions, or development of debilitating neuropathic pain distal to the injury site. It can be challenging to identify the aetiology of PNs, as the clinical syndromes are often indistinct. However, the mechanisms that underlie pathological changes in peripheral neuropathy are fundamentally different, depending on the trigger. This review focuses on the axonopathy observed in two frequently encountered forms of peripheral neuropathy, diabetic neuropathy and chemotherapy-induced neuropathy. A key manifestation of axonopathy in PN is the degeneration of terminal arbors of peripheral nerves, resulting in a loss of epidermal nerve fibres and inappropriate termination of nerve endings. Many symptoms of PN arise from aberrant termination of nerve endings, and the underlying axonopathy may be non-reversible, as nerve regeneration after injury and disease is often poor, absent, or aberrant. Directed guidance of terminal arbors back into the epidermis is therefore a suggested approach to treat peripheral neuropathy. This review will outline potential strategies to enhance and guide axonal regeneration and reinnervation in the skin. Using diabetic neuropathy and chemotherapy-induced neuropathy as specific examples, this review examines the setbacks encountered with the translation of growth factors into therapeutics for human neuropathy, and suggests a number of approaches for topical drug delivery.",
keywords = "Axonopathy, Chemotherapy-induced neuropathy, Cisplatin, Diabetic neuropathy, Paclitaxel, Peripheral neuropathy",
author = "Landowski, {Lila M.} and Dyck, {P. James B} and Engelstad, {Ja Nean} and Taylor, {Bruce V.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.jchemneu.2016.04.006",
language = "English (US)",
volume = "76",
pages = "19--27",
journal = "Journal of Chemical Neuroanatomy",
issn = "0891-0618",
publisher = "Elsevier",

}

TY - JOUR

T1 - Axonopathy in peripheral neuropathies

T2 - Mechanisms and therapeutic approaches for regeneration

AU - Landowski, Lila M.

AU - Dyck, P. James B

AU - Engelstad, Ja Nean

AU - Taylor, Bruce V.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Peripheral neuropathies (PNs) are injuries or diseases of the nerves which arise from varied aetiology, including metabolic disease, trauma and drug toxicity. The clinical presentation depends on the type of neuropathy, and may include the loss of motor, sensory and autonomic functions, or development of debilitating neuropathic pain distal to the injury site. It can be challenging to identify the aetiology of PNs, as the clinical syndromes are often indistinct. However, the mechanisms that underlie pathological changes in peripheral neuropathy are fundamentally different, depending on the trigger. This review focuses on the axonopathy observed in two frequently encountered forms of peripheral neuropathy, diabetic neuropathy and chemotherapy-induced neuropathy. A key manifestation of axonopathy in PN is the degeneration of terminal arbors of peripheral nerves, resulting in a loss of epidermal nerve fibres and inappropriate termination of nerve endings. Many symptoms of PN arise from aberrant termination of nerve endings, and the underlying axonopathy may be non-reversible, as nerve regeneration after injury and disease is often poor, absent, or aberrant. Directed guidance of terminal arbors back into the epidermis is therefore a suggested approach to treat peripheral neuropathy. This review will outline potential strategies to enhance and guide axonal regeneration and reinnervation in the skin. Using diabetic neuropathy and chemotherapy-induced neuropathy as specific examples, this review examines the setbacks encountered with the translation of growth factors into therapeutics for human neuropathy, and suggests a number of approaches for topical drug delivery.

AB - Peripheral neuropathies (PNs) are injuries or diseases of the nerves which arise from varied aetiology, including metabolic disease, trauma and drug toxicity. The clinical presentation depends on the type of neuropathy, and may include the loss of motor, sensory and autonomic functions, or development of debilitating neuropathic pain distal to the injury site. It can be challenging to identify the aetiology of PNs, as the clinical syndromes are often indistinct. However, the mechanisms that underlie pathological changes in peripheral neuropathy are fundamentally different, depending on the trigger. This review focuses on the axonopathy observed in two frequently encountered forms of peripheral neuropathy, diabetic neuropathy and chemotherapy-induced neuropathy. A key manifestation of axonopathy in PN is the degeneration of terminal arbors of peripheral nerves, resulting in a loss of epidermal nerve fibres and inappropriate termination of nerve endings. Many symptoms of PN arise from aberrant termination of nerve endings, and the underlying axonopathy may be non-reversible, as nerve regeneration after injury and disease is often poor, absent, or aberrant. Directed guidance of terminal arbors back into the epidermis is therefore a suggested approach to treat peripheral neuropathy. This review will outline potential strategies to enhance and guide axonal regeneration and reinnervation in the skin. Using diabetic neuropathy and chemotherapy-induced neuropathy as specific examples, this review examines the setbacks encountered with the translation of growth factors into therapeutics for human neuropathy, and suggests a number of approaches for topical drug delivery.

KW - Axonopathy

KW - Chemotherapy-induced neuropathy

KW - Cisplatin

KW - Diabetic neuropathy

KW - Paclitaxel

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84975123115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975123115&partnerID=8YFLogxK

U2 - 10.1016/j.jchemneu.2016.04.006

DO - 10.1016/j.jchemneu.2016.04.006

M3 - Review article

VL - 76

SP - 19

EP - 27

JO - Journal of Chemical Neuroanatomy

JF - Journal of Chemical Neuroanatomy

SN - 0891-0618

ER -